ABBV
AbbVie Inc.
NYSE · USHealthcareDrug Manufacturers - General
$253.38-0.44%
Price as of Jul 20, 2026
ABBV financials
AbbVie Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $61.2B | $56.3B | $54.3B | $58.1B |
| Cost of revenue | $18.2B | $16.9B | $20.4B | $17.4B |
| Gross profit | $43.0B | $39.4B | $33.9B | $40.6B |
| Operating expenses | $22.9B | $30.3B | $21.1B | $22.5B |
| Operating income | $20.1B | $9.1B | $12.8B | $18.1B |
| Net income | $4.2B | $4.3B | $4.9B | $11.8B |
| EBITDA | $17.6B | $14.9B | $17.2B | $24.2B |
| Basic EPS | $2.37 | $2.40 | $2.73 | $6.65 |
| Diluted EPS | $2.37 | $2.39 | $2.72 | $6.63 |
| Balance sheet | ||||
| Cash & equivalents | $5.2B | $5.5B | $12.8B | $9.2B |
| Total assets | $134.0B | $135.2B | $134.7B | $138.8B |
| Total liabilities | $137.2B | $131.8B | $124.3B | $121.5B |
| Stockholders’ equity | -$3.3B | $3.3B | $10.4B | $17.3B |
| Total debt | $69.1B | $67.8B | $60.1B | $64.2B |
| Net debt | $63.8B | $62.3B | $47.3B | $55.0B |
| Cash flow | ||||
| Operating cash flow | $19.0B | $18.8B | $22.8B | $24.9B |
| Capital expenditure | -$1.2B | -$974.0M | -$777.0M | -$695.0M |
| Free cash flow | $17.8B | $17.8B | $22.1B | $24.2B |
| Dividends paid | -$11.7B | -$11.0B | -$10.5B | -$10.0B |
| Share repurchases | -$980.0M | -$1.7B | -$2.0B | -$1.5B |